Stock SOLARA SOLARA ACTIVE PHARMA SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Solara Active Pharma Sciences Limited

Equities

SOLARA

INE624Z01016

Market Closed - NSE India S.E.
Other stock markets
 09:03:24 2024-04-25 am EDT 		5-day change 1st Jan Change
560.8 INR +1.67% Intraday chart for Solara Active Pharma Sciences Limited +32.53% +55.28%
Apr. 08 Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director CI
Mar. 26 Solara Active Pharma Gets Board Nod to Sell 100% Stake in SeQuent Penems MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Weaknesses

  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SOLARA ACTIVE PHARMA SCIENCES LIMITED Stock Solara Active Pharma Sciences Limited
+55.28% 238M -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.17% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.29% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.04% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.68% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 219B
B+
NOVARTIS AG Stock Novartis AG
+6.04% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.51% 196B
A+
PFIZER, INC. Stock Pfizer, Inc.
-12.10% 149B
C+
AMGEN INC. Stock Amgen Inc.
-6.41% 146B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SOLARA Stock
  4. Ratings Solara Active Pharma Sciences Limited